Home > Insider Trading > Filing (0001385508-19-000004)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1385508	Opiant Pharmaceuticals Inc.	OPNT	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1358116	Phil Skolnick	C/O Opiant Pharmaceuticals, Inc. 201 Santa Monica Blvd., Suite 500 Santa Monica CA 90401	Chief Scientific Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-01-02	10,000	$9.00	10,000	No	4	M	Direct
Common Stock	Disposition	2019-01-02	7,768	$13.84	2,232	No	4	S	Direct
Common Stock	Disposition	2019-01-04	2,232	$13.48	0	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Stock Option (right to buy)	Disposition	2019-01-02	10,000	$0.00	10,000	$9.00
Common Stock	Stock Option (right to buy)	Acquisiton	2019-01-03	13,200	$0.00	13,200	$13.61

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
160,000	2018-08-06	2027-02-06	No	4	M	Direct
13,200		2029-01-02	No	4	A	Direct

Footnotes

The option was exercised pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
The shares were sold pursuant to a Rule 10b5-1 trading plan entered into by the Reporting Person.
This transaction was executed in multiple trades at prices ranging from $13.61 to $14.02. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
This transaction was executed in multiple trades at prices ranging from $13.47 to $13.61. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
On January 3, 2019, the reporting person was granted an option to purchase 13,200 shares of common stock. The option vests as follows: 1/48 of the options become exercisable on the first monthly anniversary of the vesting commencement date, and 1/48 of the options become exercisable on such date every month thereafter through the fourth anniversary of the Grant Date.